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Abstract 
The benefits of melatonin on human body are drawing increasing attention from several researchers in 
different fields. While its role as cure for sleep disturbances (e.g., jet lag, insomnia) is well documented and 
established, new functions in physiological and pathophysiological processes are emerging. To investigate 
these effects, there is need for the characterization of melatonin transport processes in the body and 
resulting pharmacokinetics. Although recent works propose physiologically-based pharmacokinetic 
modelling of melatonin, no work has yet highlighted the potential of PBPK simulations to shed light on 
melatonin pharmacokinetic aspects and discrimination among administration routes. This paper presents, 
validates, and discusses a versatile PBPK model featuring different ways of administration and compares 
the resulting pharmacokinetic profiles of intravenous, oral, and transdermal administration, with the goal 
of understanding which is the optimal route to achieve either physiological and/or supraphysiological 
melatonin levels. 
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Introduction 
In recent years, physiologically-based pharmacokinetic (PBPK) models have become widely-used and 
accepted tools to study, simulate, and predict drugs concentration in the body as well as provide insight on 
their pharmacological effects via combination with pharmacodynamic models. PBPK models are currently 
applied throughout the phases of drug discovery and development with various goals, e.g., inter-species 
extrapolation, analysis of chemical toxicity or efficiency, investigation of different routes of administration, 
and study of inter-individual variability [1-5]. Indeed, PBPK simulations are extremely useful to study the 
pharmacokinetic differences among individuals, from pediatric patients [6] to healthy adults to special 
subjects, with particular conditions (e.g., pregnancy [7]) or specific diseases with high probability of 
affecting drugs pharmacokinetics (e.g., renal insufficiency or liver diseases). The reason is that PBPK models 
(first theorized in 1937 by Teorell [8]) incorporate the anatomy and physiology of the patients’ body into 
the mathematical description of drugs absorption, distribution, metabolism, and elimination (ADME) 
processes. Their recent success is also related to the current availability of modern tools to solve complex 
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mathematical problems, such as systems of ordinary differential equations (ODEs) with a large number of 
parameters. In silico simulations are appealing because of the possibility to carry out “free” and fast 
experiments [9], compared to the actual clinical trials, whose costs and duration have increased over the 
past 20 years [10]. 
Not only drug discovery and development [11], but also the clinical practice may take advantage from 
simulation via PBPK models, as it tackles the problem of selecting the optimal dose that maximizes 
therapeutic efficacy while minimizing adverse effects. On one hand, inter-individual variability and 
medication errors are significant obstacles in this decision, on the other hand, the choice of the optimal 
administration route and dosing regimen are crucial degrees of freedom of this problem. 
In this respect, melatonin is a useful and interesting case-study. The pleiotropic functions of melatonin 
in the human body are catalyzing the attention of several researchers in different fields, and its exogenous 
administration can follow different pathways. Although melatonin is particularly popular as a cure for sleep 
disturbances (i.e. jet-lag, insomnia), a number of other physiological and pathophysiological functions have 
been investigated and are still emerging. For instance, receptor-mediated actions include regulatory 
functions, e.g., immune response, homeostasis, and blood pressure regulation [12-16]. Indeed, melatonin 
receptors are distributed in the whole body. Besides, non-receptor mediated actions are of great interest, 
especially the potency of its antioxidant, antiproliferative, and anti-inflammatory action via radical 
scavenging [17]. The application in chemotherapy in combination with other substances improves both the 
chances of survival and quality of the patients’ life [18]. 
In healthy people, melatonin is endogenously produced by the pineal gland. The production rhythm is 
entrained with the day-night cycle, with darkness causing the onset around 9-10 PM, peak between 2-4 AM 
(with Cmax range 60-100 pg/mL), and baseline low values during the day at about 5-10 pg/mL [19]. However, 
this endogenous rhythm may be subject to either disruption or levels reduction, and medical doctors think 
that this has negative impact on the patients’ health status, especially in critically ills [20-22]. 
 In order to identify the optimal melatonin dosage, a detailed characterization of exogenous melatonin 
ADME processes within the human body is recommended. Through the years, several authors have carried 
out pharmacokinetic studies to identify the most suitable dosage and route of administration to produce 
physiological and supraphysiological melatonin levels in different populations [23-26]. Although some 
recent works exist on the PBPK modelling of melatonin in the human body (e.g., [27]), our aim is not only to 
provide a valuable PBPK model but also to compare melatonin levels that result from different routes of 
administration, i.e. intravenous (IV), oral (per os, PO), and transdermal (TD). The first goal is to understand 
which route has the highest potential to reproduce the endogenous profile of healthy patients, with the 
purpose of restoring melatonin physiological roles. The second goal is to identify the routes that allow 
achieving higher levels, with the purpose of producing pharmacological effects (for instance strong anti-
oxidative action for ICU, intensive care unit, patients). Despite high inter-individual variability that is typical 
of melatonin pharmacokinetics (e.g., related to different physical characteristics, genetic factors, and 
presence of impairments/diseases), we intend to show that in silico simulations can provide guidance and 
advice in selecting the optimal routes of administration and dosage, once the reliability of the employed 
model is verified. Indeed, model simulations constitute a powerful tool for optimal pharmacotherapy, 
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Methods 
In general, the PBPK approach combines anatomical and physiological aspects with mathematical 
modeling, by assuming that the organs and tissues of the human body can be represented by 
compartments with homogeneous concentration. The reference model of this work (from [28]) considers 8 
compartments in the description of the human body: Plasma, Gastric Lumen (GL), Small Intestinal Lumen 
(SIL), Large Intestinal Lumen (LIL), Liver, Gastro-Intestinal Circulatory System (GICS), Poorly perfused Tissues 
(PT), and Highly perfused Organs (HO). Actually, some compartments represent single organs while other 
compartments represent lumped parts so to reduce the number of model parameters. In fact, a too high 
number of parameters may lead to mathematical predicaments of over-parameterization and model 
identification (see [10] for an exhaustive discussion on this topic). The HO compartment stands for organs 
that are highly perfused by blood, i.e. kidneys, lungs, spleen, and heart. The PT compartment lumps tissues 
that are poorly reached by blood vessels, e.g., adipose tissue, skin, and muscles (specifically in ill/treated 
patients). The GICS compartment lumps the portal vein, the mesenteric artery, and the microcirculatory 
blood vessels of the gastrointestinal system. 
We applied some modifications to this basic structure of the model to adapt it to melatonin 
pharmacokinetic features. Particularly, we added (i) the pineal gland, and (ii) the salivary glands. Pineal 
gland is the source of endogenous melatonin. Within our PBPK model, the material balance on the pineal 
gland accounts for the production of endogenous melatonin with a term that exhibits a 24-h periodicity 
(see [2]). Several authors evaluate melatonin endogenous and exogenous amount by measuring either 
saliva and plasma or only saliva concentrations [29-32]. Thus, we found more correct (from a physiological 
point of view) to add the salivary glands to the model compartments. The drug material balances, in the 
form of an ODE system, describe the concentration dynamics of melatonin in each compartment. Finally, an 
additional equation allows accounting for the dynamics of melatonin main metabolite 6-sulfatoxymelatonin 
(aMT6s). 
In case of IV route, the drug directly inputs the Plasma compartment. Conversely, in case of PO 
administration, the drug enters the GL and moves through SIL and LIL to be absorbed through the intestinal 
walls and conveyed to Liver via the portal vein. This results into the so called “first-pass metabolism effect”. 
After that, it is drained from the Liver to reach the systemic circulation and distributes to the other organs 
and tissues via the bloodstream. It is worth stressing that the model structure takes into consideration GL, 
SIL, and LIL only in case of PO administration. In fact, in other cases, we assume that the drug counter-
diffusion from GICS to SIL and LIL is negligible, and therefore it is possible to neglect such compartments, 
along with GL and reduce significantly the number of ODEs. We do not report here the complete 
mathematical description of the model, as it is extensively detailed in [10,28]. 
While in case of IV and PO routes, the skin is incorporated into the PT compartment, in case of TD 
administration the skin becomes the mean for drug absorption and therefore calls for a specific and 
detailed description. In particular, melatonin evolution has to be considered not only in time but also along 
the skin depth coordinate. Thus, the homogenous approach (based on the perfectly mixed hypothesis) to 
compartment modeling is replaced and the resulting skin mathematical description involves partial 
differential equations (PDEs) with suitable boundary conditions [2]. Particularly, three skin layers are 
considered: (i) stratum corneum that is the most external and thinnest but also the main barrier, (ii) viable 
epidermis that may constitute a metabolism site, and (iii) dermis, from which the drug is supposed to reach 
the systemic circulation via the contained blood vessels, and then distribute to the rest of the body. 
In case of TD administration, the PDEs describing the skin and the ODEs describing the rest of the body 
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are combined via the finite differences method. In fact, the PDEs are discretized respect to the spatial 
coordinate (i.e. skin depth) and therefore converted to ODEs [2]. 
Independently of the administration pathway, the model parameters can be divided into three 
categories: (i) individualized, (ii) assigned, and (iii) regressed. Individualized parameters (e.g., volumes of 
compartments and flowrates among them) are calculated according to empirical correlations that are 
available in the literature and depend on the patients’ physical characteristics. We consider as specific 
features the sex, body weight, and height. Assigned parameters are some drug physicochemical properties 
whose value can be determined from the scientific literature (e.g., protein binding). Some parameters, 
strictly related to the transport properties, can be neither found in the literature nor calculated by empirical 
correlations (e.g., diffusivity, transfer coefficients, metabolic constants), thus they are obtained via a non-
linear regression procedure respect to experimental data from the literature. Indeed, although the value of 
some transfer coefficients might be determined from in vitro studies, such experiments would not account 
for the interactions among organs and tissues in the living organism, and therefore would affect the 
reliability of the mathematical model and consistency/validity of the simulated results. 
Once the model transfer coefficients and metabolic constants are identified (with data from [33] for IV 
route, [34] and [29] for PO, and [35] for TD), a model validation with additional experimental 
pharmacokinetic data allows assessing its prediction capability. To do so, we chose (i) the median squared 
error (MeSE) (Eq. (1)) over the mean squared error (MSE) [27] for robustness reasons, (ii) the difference 
between the experimental area under the curve AUCexp and the model prediction AUCmod ([28], Eq. (2)), and 
(iii) the difference between the observed and predicted values of Cmax. Comments on the difference 
between the observed and predicted values of Tmax are also present. The AUC is calculated via trapezoidal 
rule over the NM measured concentration values. We consider satisfactory MeSE values below 0.1 [ng/mL] 
and %ΔAUC values below 30 %. 
  
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    (2) 
Once the prediction capability of the PBPK model is evaluated, it is interesting to assess in silico the 
optimal administration route. In particular, we investigated three distinct administration routes: (i) IV 
continuous infusion over 7 h, (ii) PO in both the immediate and controlled release (CR) formulations (the 
last one with a release time of 7 h), and (iii) TD with a standard patch of 10 cm2. The PO (CR) tablet release 
is modeled according to the dissolution characteristics elucidated in [36] and employed in [35]. Results from 
all the administration routes are compared for an assigned dose range between 0.75-12 mg, grounding on 
the state-of-art pharmacokinetic studies on exogenous melatonin administration. For this preliminary 
study, we do not consider high doses [37]. Our virtual subject is a healthy adult male of 80 kg and 185 cm. 
To provide a quantitative comparison of the pharmacokinetics resulting from the three administration 
routes, we calculate and compare the AUC and the maximum concentration Cmax. Finally, we comment on 
the concentration dynamics in the different compartments of the body that result by simulating the 
administration of melatonin 3 mg via IV, PO, and TD routes to the same in silico patient. For an unbiased 
comparison of melatonin ADME, we intentionally neglected the endogenous melatonin production. 
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Results and Discussion 
We computed the prediction performance with data coming from melatonin pharmacokinetic studies. 
The validation cases for each route of administration are proposed and discussed. 
IV validation case 
Figure 1 shows the model curve resulting from the simulation of 20 µg IV infusion over 5 h to 6 healthy 
subjects (A-F panels) and 1 individual subjected to pinealectomy 2 years earlier (G panel), as in [39]. 
Experimental data (red diamonds) show the individual pharmacokinetic profiles. The model performance 
(i.e. the blue line) is acceptable, but for A panel of Figure 1. Nevertheless, the values of the performance 
indexes (see Table 1) remain quite satisfactory, as even the AUC value of that patient (A panel) is only 
slightly higher than 30 %. It is worth observing that the experimental inter-individual variability of 
melatonin levels is reduced in case of IV administration if compared to other routes (see also Figure 2 and 
Figure 3). As a result, also confidence intervals of the IV model parameters are narrower (see values Tables 
A-C reported in Appendix). Figure 1 (G panel) shows the experimental trend for the pinealectomized patient 
where the model performance is as good as for the others. The IV model was further tested with 
experimental results of additional patients from the same study (subjected to bolus injection) and 
supplementary validation cases [34,39], for which the results of the %ΔAUC, %ΔCmax, and MeSE (not 
reported) are adequate as well. In this case, we do not calculate the experimental/predicted Tmax and the 
relative error, because in case of IV constant rate of infusion the Tmax corresponds to the infusion duration 
(i.e. in this case study, equal to 5 h). 
Table 1 - Performance indexes %ΔAUC , %ΔCmax, and MeSE 
values for the IV validation case. 
Patient % AUC  % maxC  MeSE  
A 31.2 32.1 2.4e-4 
B 18.8 24.5 2.6e-4 
C 14.2 13.4 4.6e-5 
D 20.6 10.1 8.3e-5 
E 10.5 10.4 2.0e-5 
F 16.3 31.8 4.5e-5 
G 0.7 6.4 5.1e-5 
PO validation case 
Figure 2 shows experimental results on melatonin concentration in case of PO administration. The blue 
line in Figure 2 (A and B panels) simulates the pharmacokinetics after administration of 2 and 4 mg 
respectively, to 12 healthy volunteers [33]. The experimental data (red diamonds) show mean 
concentration values of the volunteers group. Figure 2 (C panel) shows both individual (red dots) and 
median (black diamonds) concentration profiles of 5 healthy subjects administered with 50 mg [25]. Finally, 
Figure 2 (D panel) shows the simulation (blue line) of the averaged profile of 5 healthy subjects 
administered with 2 mg [40]. In all these cases, only a single curve is displayed, because the literature data 
report only averaged demographic and/or pharmacokinetic data. Despite the literature differences in 
features and dosages, the model performance is acceptable as the simulation curve is near to the average 
experimental profile in all the cases. In fact, Table 2 lists low values of MeSE, except for Figure 2 (C panel).  
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Figure 1 - Experimental data (red diamonds, [37]) represent the pharmacokinetics of 6 healthy subjects (A-F 
panels) and 1 pinealectomized patient (G panel) who received IV 20 µg infused over 5 h. The blue continuous 
line is the model-simulated pharmacokinetic profile. 
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It is worth observing that the simulated profile (i.e. blue line) anticipates the experimental data (see 
Figure 2 (A, B, and C panels)). The difference between the observed and predicted Tmax is about 30 min. This 
may be related to digestion features and to the patients’ condition (e.g., fed or fasting). Future work should 
adapt the PO model to such issues. However, the observed Tmax depends also on the experimental protocol, 
and in particular, on the blood sampling time. In addition, this parameter is affected by a certain degree of 
experimental error. The %ΔAUC in Table 2 is always below 15 % while the relative error between the 
observed and predicted Cmax is below 15 % except for case A. It is fair to acknowledge that the 
pharmacokinetics resulting from the PO route features a higher degree of inter- and intra-individual 
variability compared to the IV route, because of several interacting factors that affect absorption (e.g., pH, 
stomach emptying time, intestinal transit times, and variation of blood supply to stomach and intestine) 
and metabolism (e.g., genetic factors and presence of diseases). In fact, MeSE results for the IV validation 
cases are at least one order of magnitude lower and, consistently, confidence intervals of the model 
parameters are larger (Table B in Appendix). Additional case studies are employed for validation, with 
similar results in terms of performance assessment [39]. 
  
  
Figure 2 - A-B panels: experimental data (red diamonds, [33]), represent the average pharmacokinetics of 12 
subjects administered with melatonin PO 2 and 4 mg. C panel: experimental individual (red dots) and median 
(black diamonds) pharmacokinetics after melatonin PO 50 mg [25]. D panel: experimental data (red 
diamonds) averaged over 5 healthy subjects from [40] (melatonin PO 2 mg). The blue continuous line is the 
model-simulated pharmacokinetic profile. 
TD validation case 
Figure 3 shows a validation case from [41] for the TD route. In the study, melatonin was administered 
2.1 mg/12 cm2 as TD patch. Since the reported demographic data consist only of averaged measures over 
the subjects’ group, the model curve (blue line) is the pharmacokinetics of an averaged individual, while red 
diamonds represent the experimental values of melatonin concentration of the individuals who took part to 
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the study, connected with red lines for the sake of clarity. The model prediction is quite near to three out of 
four individual trends. The most distant individual trend shows atypical pharmacological levels, which may 
be related to either differences in the skin features of that specific subject and/or melatonin dermal 
deposition [41]. This results into a nonsensical value of %ΔAUC (Table 3). In general, TD pharmacokinetic data 
show high inter-individual variability having to do with the process of transdermal absorption [41]. This 
aspect is also reflected in the confidence intervals of the model parameters (Table C in Appendix) and in the 
variability of observed Cmax and Tmax values, although it should be remarked that blood sampling occurred 
every hour. Thus, it is not guaranteed that the real experimental maximum value corresponds to the 
observed Cmax. In any case, the %ΔCmax is around 25-30 % for the first three individuals. As far as the Tmax is 
concerned, it is worth observing that the model seems to predict a slower absorption compared to the 
experimental trend. Despite the high values of %ΔAUC, it is likely that the reliability of the model for this 
route might further improve by relying on a higher number of experimental data sets for the identification 
of the parameters. 
Table 2 - Performance indexes %ΔAUC and MeSE values for the 
PO validation case. 
Panel % AUC  % maxC  MeSE  
A 2.6 40.1 0.009 
B 7.3 13.5 0.103 
C 14.3 10.7 5.68 
D 8.4 5.0 0.004 
 
Figure 3 - Experimental data (red diamonds, [41]) are the individual pharmacokinetic trends, resulting from 
melatonin TD 2.1 mg over 12 cm
2
 patch administration. The blue continuous line is the model-simulated 
pharmacokinetic profile of the averaged subject. 
 
Table 3 - Performance indexes %ΔAUC, %ΔCmax, and MeSE 
values for the TD validation case. 
Patient % AUC  % maxC  MeSE  
1 39.1 34.9 8.2e-4 
2 38.1 27.7 2.1e-4 
3 26.2 23.6 5.4e-5 
4 >100 >100 4.0e-3 
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For all the considered routes (i.e. IV, PO, and TD), the results are acceptable enough to continue with the 
analysis of melatonin ADME in the body as a function of the different administration pathways. 
In silico simulations for optimal dose selection 
A number of pharmacokinetic studies focuses on selecting the optimal dose that produces either 
physiological (e.g., [38]) or supraphysiological levels. In fact, while physiological levels can improve sleep 
maintenance and resynchronize circadian rhythms [17], supraphysiological levels may produce strong 
antioxidant action [25] and analgesic effects [37]. To investigate melatonin pharmacokinetic properties, a 
few studies compare the in vivo results of different routes of administration [34], and/or specific 
populations (e.g., elderly [26], critically ills [24], patients suffering from severe oxidative stress [25]). To 
prove the efficiency of in silico simulations within this context, we compare the pharmacokinetic profile 
resulting from three different routes, with doses ranging from 0.75 to 12 mg. The selected range is 
considered safe as it has been covered by a number of pharmacokinetic studies. Figure 4 shows the results 
of the simulations, along with comparison to experimental data of endogenous profile in healthy adult 
volunteers from [32]. 
As expected, smoother and more sustained levels are achieved via TD and PO (CR) formulations. The 
slow absorption phase, which is characteristic of TD release, proves particularly suitable for mimicking the 
endogenous levels produced by the pineal gland. Equally, the PO (CR) solution provides sustained levels as 
well (Tmax about 4 h), coupled with a steeper absorption (see especially the case of 0.75 mg). This difference 
in the velocity of absorption has to be considered in the choice of the administration time, as this will affect 
the onset time of melatonin effects. In case of PO (CR) 0.75 mg administration, shifting the time of 
administration would allow quite a close imitation of the endogenous profile. The same consideration holds 
for the case of TD 6 mg administration. Thus, not only dosing, but also the time of administration is a key 
degree of freedom in the problem of melatonin delivery optimization to restore/produce physiological 
levels. Failing in considering this aspect would likely result into unsatisfactory outcomes in terms of 
pharmacodynamic effects. In this sense, PBPK simulations can be used as a tool for therapy design, to 
determine the time of administration that more likely leads to the desired effects. It should also be noted 
that, although the TD route produces sustained levels over 24 h, it is unlikely that the subject will manifest 
adverse effects, for instance related to sleep. Firstly, levels are quite similar to the endogenous pattern (see 
the black circles), and after about 10 h, they start decreasing towards the daily baseline (black dotted line). 
Secondly, doses up to 3500 mg (PO) have been administered without any acute adverse effects and the 
scientific literature does not report any toxic threshold for melatonin dose [37]. For instance, in [37] there is 
no evidence of sedative effects for doses up to 100 mg (IV), which would produce more than 3-order-of-
magnitude higher levels than those shown in Figure 4, case 12 mg via TD route (according to our 
simulations and consistently with experimental results reported in the study). Predictably, even low doses 
of continuous IV infusion produce the highest levels and bioavailability, thus it is probably the most 
appropriate mean to reach prompt pharmacological (i.e. supraphysiological) levels. In fact, even for the 
lowest dose considered (i.e. 0.75 mg), the resulting plasma concentration is an order of magnitude higher 
than the endogenous one (see black circles compared to the blue line). On the contrary, TD administration 
should be excluded for the purpose of producing pharmacological levels (see highest doses 12 mg in Figure 
4 and Cmax value in Figure 5). Figure 4 also shows that in case of melatonin, PO immediate release 
formulation is not able to produce sustained levels. However, for doses higher than 5 mg, this 
administration route can be considered to reach pharmacological levels, alternatively to IV infusion. All of 
these considerations are confirmed by the values of the pharmacokinetic parameters AUC and Cmax, 
compared in Figure 5. The highest AUC is in fact associated with the IV continuous infusion route, whereas 
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the other routes of administration produce lower values. Another possibility to be explored is the 
combination of oral immediate release and CR formulations. 
  
  
Figure 4 - Dynamics of the melatonin plasma concentration over 24 h after IV, PO, PO (CR), and TD 
administration of 1.5 to 12 mg to a virtual subject (male, adult, 80 kg, 185 cm). Black circles describe the 
endogenous profile in healthy adult volunteers [32]. Black horizontal dashed lines indicate the range of 
endogenous Cmax in healthy subjects (60-100 pg/mL). Black dotted line marks the average value of daily 
melatonin baseline in plasma. 
 
Depending on the treatment goal, for instance the attainment of either endogenous or pharmacological 
levels, it is possible to explore additional contributing factors, other than the route, dose, and time of 
administration. In fact, different dissolution curves can be employed in the PO (CR) formulations and can be 
combined with the PBPK model to study the resulting ADME processes. The same approach can be applied 
in case of TD route, since both the features, position, and application extent of the patch are degrees of 
freedom for the medical doctor. The main degree of freedom of the IV infusion route is its duration. Once 
the main goal is assigned (in terms of ideal pharmacokinetic profile for a specific application), an 
optimization can be carried out to identify the optimal dose and dosing regimen by considering those 
additional degrees of freedom. 
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Figure 5 - Comparison of pharmacokinetic parameters Cmax (left panel) and AUC (right panel) resulting from 
the three routes of administration. The x-axis reports the simulated dose range, i.e. 0.75 to 12 mg. 
 
Since melatonin roles affect several organs and tissues, with cerebral, immune, gastrointestinal, 
cardiovascular, renal, and endocrine functions [12], and melatonin receptors are distributed in the whole 
body, model compartment levels should be visualized and discussed, as well. Figure 6 shows the simulation 
in different compartments for 3 mg administered IV, PO, PO (CR), and TD. The slow drug absorption, typical 
of TD administration, is reflected in the slow distribution to the organs/tissues of the body. Conversely, IV 
infusion induces higher levels in all the compartments (see Highly perfused Organs and Liver compartments 
in Figure 6). Thus, in case the goal of melatonin administration is a diffused anti-oxidant action in the 
patient body via radicals scavenging, this route should be preferred. The same can be stated in case of 
immune system enhancement (hence with potential beneficial effects in terms of cancer cells detection 
and elimination). In addition, when target organs are the highly perfused ones (e.g., pancreas, liver, and 
kidneys), this route should be definitely considered. When a more localized target action is required, it 
should be considered that in case of PO administration, higher levels are expected in the liver and 
gastrointestinal tract, as confirmed by the model simulation. According to [14], melatonin is gastro-
protective at endogenous levels, whereas pharmacological levels of melatonin (in combination with other 
drugs) contribute to healing of gastroduodenal ulcers. The difference of goal (i.e. gastro-protection vs 
healing of local ulcer) will be the discriminating factor for selecting the most suitable dose to produce either 
endogenous or higher levels. The velocity of excretion via the kidneys is comparable for both the IV and PO 
routes, and is faster for these routes when compared to TD. Concluding, anatomical and physiological 
considerations can be converted into quantitative data to be carefully assessed, analyzed, and visualized via 
PBPK model simulations. This kind of information is not only useful when several routes of administration 
are viable, but also especially important when the drug target site is not plasma. 
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Figure 6 - Simulation of the melatonin concentration dynamics in the compartments Saliva, Liver, Highly and 
Poorly perfused Organs/Tissues, and the Kidneys-excreted amount after administration of 3 mg via IV, PO, PO 
(CR), and TD. 
Conclusions 
While PBPK simulators allow evaluating melatonin levels in plasma and the rest of the body, further 
practical considerations should support the pharmacokinetic investigation with the aim of achieving 
optimal clinical efficacy. In fact, while IV route may hold the advantage of the highest bioavailability and 
fastest distribution to organs and tissues, most of the patients may find it distressing. Therefore, it may 
result suitable only for specific categories such as critically ill patients, who usually receive continuous 
infusion of different drugs and enteral nutrition for quite long periods. On one hand, PO route is easy and 
simple but it is subject to first-pass hepatic metabolism, which implies a certain degree of inter-individual 
variability related to different metabolism characteristics, and different patients’ features (e.g., 
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gastrointestinal pH, temperature, and other previously mentioned factors). As well as PO (CR) option, TD 
route allows obtaining sustained levels and avoids first-pass hepatic metabolism. On the other hand, it is 
subject to slow absorption through skin, possible metabolism within viable epidermis, and high inter- and 
intra-individual variability related to different skin features. 
In this work, we introduced and discussed a case-study to compare pharmacokinetic levels resulting 
from different doses and three administration routes, i.e. IV, PO, and TD, also considering both oral 
immediate release and CR formulations. PBPK simulations are particularly interesting for their intrinsic 
nature and structure, because they provide quantitative information on the drug ADME processes in the 
body. Besides, coupling with intelligent drug design and in vitro experiments enhances the potential to 
maximize their efficacy. As far as melatonin is concerned and with reference to both practical and 
pharmacokinetic aspects, it is possible to conclude that PO (CR) and TD routes represent the best options in 
case of disruption of the endogenous rhythm (e.g., in people suffering from either insomnia or jet-lag and 
critically ills). Equally, PO (with doses significantly higher than 3 mg) and IV infusion are preferable when 
higher concentration levels are required for other goals, for instance to contrast severe oxidative stress and 
possibly cancer, and target specific organs as sites of pharmacological action. This work can be extended 
and improved by focusing on one administration route and running a numerical optimization of the 
melatonin dose respect to a target trajectory, also considering a number of degrees of freedom depending 
on the selected route. It is also worth stressing the transferability of the presented approach to any other 
drugs that are versatile from the point of view of the administration routes. Such investigations may 
become especially interesting in case of drugs with narrow therapeutic windows, such as chemotherapy 
drugs whose pharmacokinetics quantification is essential and critical. 
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Appendix 
 
Table A. – Key model parameters in case of the IV route, correlated by 90 % confidence intervals. 
Parameters Description Regressed values 90 % 𝑪𝑰𝒍𝒃 90 % 𝑪𝑰𝒖𝒃 
𝒌𝑻−𝑷 [ 𝒎𝒊𝒏
−𝟏] Plasma-poor tissues 
transfer coefficient 
0.3955 0.373 0.418 
𝒌𝑷−𝑻 [ 𝒎𝒊𝒏
−𝟏] Poor-tissues plasma 
transfer coefficient 
0.8 0.774 0.826 
𝒌𝑯𝑷−𝑷 [ 𝒎𝒊𝒏
−𝟏] Highly perfused organs- 
plasma transfer coefficient 
0.047 0.045 0.05 
𝒌𝑷−𝑯𝑷 [ 𝒎𝒊𝒏
−𝟏] Plasma-highly perfused 
organs transfer coefficient 
1.48 1.416 1.544 
 
Table B. – Key model parameters in case of the PO route, correlated by 90 % confidence intervals. 
Parameters Description Regressed values 90 % 𝑪𝑰𝒍𝒃 90 % 𝑪𝑰𝒖𝒃 
𝒌𝑨,𝑺𝑰𝑳 [ 𝒎𝒊𝒏
−𝟏] 𝑆𝐼𝐿 absorption constant 2.205 0.245 5.655 
𝒌𝑪𝑨,𝑺𝑰𝑳 [ 𝒎𝒊𝒏
−𝟏] 𝑆𝐼𝐿 counter-diffusion 
constant 
2.920 0.158 5.683 
𝒌𝑨,𝑳𝑰𝑳 [ 𝒎𝒊𝒏
−𝟏] 𝐿𝐼𝐿 absorption constant 0.167 0.003 0.337 
𝒌𝑪𝑨,𝑳𝑰𝑳 [ 𝒎𝒊𝒏
−𝟏] 𝐿𝐼𝐿 counter-diffusion 
constant 
0.455 0.059 0.851 
𝑬𝒇𝒇𝑯 [ −] Hepatic metabolism 
efficiency 
0.467 0.235 0.699 
𝑬𝒇𝒇𝑲 [ −] Kidneys excretion 
efficiency 
0.053 0. 007 0.113 
 
Table C. – Key model parameters in case of the TD route, correlated by 90 % confidence intervals. 












𝐷𝐸 Diffusivity 2.776 ∗ 10−3 1.395 ∗ 10−3 6.946 ∗ 10−3 
𝒌𝒑𝒂𝒓𝒕𝟏 [−] 𝑆𝐶/𝑉𝐸 Partition 
coefficient 
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